Role of Glucose-Lowering Medications in Erectile Dysfunction.
Angelo CignarelliValentina Annamaria GenchiRossella D'OriaFiorella GiordanoIrene CarusoSebastio PerriniAnnalisa NatalicchioLuigi LaviolaFrancesco GiorginoPublished in: Journal of clinical medicine (2021)
Erectile dysfunction (ED) is a long-term complication of type 2 diabetes (T2D) widely known to affect the quality of life. Several aspects of altered metabolism in individuals with T2D may help to compromise the penile vasculature structure and functions, thus exacerbating the imbalance between smooth muscle contractility and relaxation. Among these, advanced glycation end-products and reactive oxygen species derived from a hyperglycaemic state are known to accelerate endothelial dysfunction by lowering nitric oxide bioavailability, the essential stimulus of relaxation. Although several studies have explained the pathogenetic mechanisms involved in the generation of erectile failure, few studies to date have described the efficacy of glucose-lowering medications in the restoration of normal sexual activity. Herein, we will present current knowledge about the main starters of the pathophysiology of diabetic ED and explore the role of different anti-diabetes therapies in the potential remission of ED, highlighting specific pathways whose activation or inhibition could be fundamental for sexual care in a diabetes setting.
Keyphrases
- type diabetes
- smooth muscle
- emergency department
- glycemic control
- blood glucose
- nitric oxide
- reactive oxygen species
- healthcare
- cardiovascular disease
- case control
- mental health
- palliative care
- single molecule
- insulin resistance
- quality improvement
- nitric oxide synthase
- hydrogen peroxide
- disease activity
- rheumatoid arthritis
- prostate cancer
- blood pressure
- metabolic syndrome
- radical prostatectomy
- chronic pain
- wound healing
- benign prostatic hyperplasia
- health insurance
- weight loss
- affordable care act